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1. Introduction
Myocarditis is an uncommon but potentially life-threatening presentation in pediatric patients
requiring critical care transport. Patients may present with malignant arrhythmias and
hemodynamic collapse, and may require transport to a center offering extracorporeal life
support. In this chapter we aim to provide a brief overview of pediatric myocarditis, with a
particular focus on considerations for stabilization and transport in acute fulminant myocar‐
ditis. These considerations include intubation and ventilation, hemodynamic support,
induction of anesthesia and pharmacological considerations for sedation, patient triage, and
choice of an appropriate receiving center.
1.1. Etiology
Myocarditis is an acute inflammatory disease of the myocardium, classically characterized by
myocyte necrosis [1], which leads to ventricular dysfunction. There are several possible causes
of myocarditis including infectious (viral, bacterial, fungal, yeast, parasitic, and protozoan)
and non-infectious (immune mediated reactions, toxins, and other disorders). In many cases
there is no identified cause. Most cases of pediatric myocarditis with a known etiology are
caused by infections, in particular by viral infections [2]- [4], however a viral etiology may be
difficult to detect. In a recent autopsy series examining 28 cases of myocarditis, viral analysis
was done in 25 cases and was only positive in 9 of those. [5]
2. Epidemiology and clinical presentation
It has been estimated that pediatric cardiomyopathy occurs in between 1.13 and 1.24 per
100,000 patients, and more than 14% of these patients likely have cardiomyopathy from an
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infectious cause. [6]- [8] Klugman et al identified 216 cases of pediatric myocarditis over a one-
year period in 35 different children’s hospitals, making up 0.05% of all patients seen. This group
concluded that pediatric patients with myocarditis have considerable variability in their
outcomes, use more intensive care unit (ICU) resources, and die more often than children with
other diagnoses. [9] There is a broad range of clinical presentation ranging from asymptomatic
to fulminant and symptoms are often non-specific. Some patients present with constitutional
symptoms, and complaints of chest pain and fatigue are common. Additionally there may be
large variability between presentations in different age groups. Patients with cardiac dysfunc‐
tion may have syncope, heart failure, arrhythmias, or shock. [1] Fulminant myocarditis occurs
in approximately 20–30% of all cases, and clinically presents with severe hemodynamic
deterioration, cardiogenic shock, severe ventricular dysfunction, and possibly life-threatening
arrhythmias. [10] Unlike adult patients, children more commonly present with fulminant
myocarditis. [11] Myocarditis is a significant cause of sudden death and may result in the
development of cardiomyopathy in some affected children. [12], [13]
3. Diagnosis
The diagnosis of myocarditis is often difficult. In one series of 31 cases of myocarditis in a
pediatric emergency department, 57% of patients had been previously evaluated by a physi‐
cian and diagnosed with pneumonia or asthma. [14] The less controversial diagnostic modal‐
ities include chest x-ray, electrocardiogram (EKG) and echocardiogram. Sinus tachycardia on
EKG with low-voltage QRS complexes is described as a classic finding. Beyond that there may
be a variety of changes seen on EKG, including widened QRS complexes, non-specific ST
changes, axis deviation, and/or Q waves. Patients may also present with arrhythmias including
ventricular tachycardia, supraventricular tachycardia, and varying degrees of heart block.
Figure 1. EKG of a 12 year old patient with myocarditis, atrioventricular block [15]
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Figure 2. EKG (rhythm strip) of the same patient, who had ongoing severe ventricular dysfunction and developed in‐
termittent episodes of wide-complex tachycardia [15]
Figure 3. EKG (rhythm strip) of a 7 year old patient with myocarditis; wide-complex tachycardia [15]
Chest x-ray findings tend to be consistent with congestive heart failure, including cardiome‐
galy and increased pulmonary markings suggestive of pulmonary edema. Echocardiography
is a useful adjunct to assess ventricular dimensions, function, and presence of atrioventricular
valve regurgitation or pericardial effusion.
A recent review of diagnostic strategies for myocarditis concluded that enlarged ventricular
dimensions on echocardiography and elevated cardiac troponin levels were the most common
findings. [16] Troponin I has high specificity but limited sensitivity in the diagnosis of
myocarditis, despite the fact that it is otherwise a reliable and commonly available biomarker
of myocardial injury. [17] In children, cardiac troponin T has been reported to have a sensitivity
of 71% in myocarditis. [18] Other common laboratory studies include general markers of
inflammation or infection, such as complete blood count with differential, C-reactive protein
and erythrocyte sedimentation rate. It is also useful to examine markers of end organ perfusion
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including lactate, liver function tests and creatinine. These studies may help understand the
etiology and impact of the disease process, but none are specific for myocarditis.
More controversial diagnostic modalities include cardiac magnetic resonance (CMR) imaging
and endomyocardial biopsy (EMB). In general these techniques would not be employed in an
acute setting in a non-tertiary care center. CMR has the advantage of being non-invasive it
requires specialty equipment and radiologists familiar with the interpretation of findings. EMB
is controversial for a variety of reasons, especially since it is invasive and carries a risk of
adverse events. Also, myocardial inflammation tends to be patchy and may be missed by
biopsy. A recent consensus statement by the American College of Cardiology and the Euro‐
pean Society of Cardiology made a class IIa recommendation for EMB in cases of unexplained
cardiomyopathy in children. [19]
4. Transport considerations
4.1. Triage
Pediatric patients with symptomatic myocarditis should be admitted to a pediatric tertiary
care center. Klugman et al. reported that in their cohort of pediatric myocarditis patients 45%
of patients required milrinone, 35% needed epinephrine, and 25% were supported with
mechanical ventilation. Extracorporeal membrane oxygenation was needed in 7% of patients,
and cardiac transplantation in 5%. [9] When triaging the patient, consideration should be given
to the fact that any patient requiring the use of blood pressure support in the setting of acute
myocarditis may quickly deteriorate and need mechanical cardiovascular support. Extracor‐
poreal membrane oxygenation (ECMO) support is now increasingly viewed as optimal
supportive therapy in anticipation of full cardiac recovery. [20] In larger children, a ventricular
assist device (VAD) has also been used to support ventricular function during acute illness. In
a previously published paper reporting the transport a series of children with myocarditis,
there were five out of ten patients who required ECMO. Among those five patients there were
three survivors. [15] In another retrospective review of 36 cases of histologically confirmed
myocarditis ECMO was used in 4 patients (11%). [21]
4.2. Transport
It has been estimated that fewer than ten percent of hospitals with intensive care unit beds
have pediatric critical care beds. [22], [23] Therefore, pediatric admission to a tertiary intensive
care unit frequently requires patient transport. Though emergency medical service teams are
trained in basic pediatric resuscitation and stabilization, often times they do not have the
breadth of experience or advanced training which would provide for the safest transport of
the critically ill child. The use of a critical care transport teams on the other hand is strongly
associated with decreased complication rates. [24]- [27] In particular for pediatric patients, the
chance of an unplanned airway or cardiovascular event was 22 times greater when a critical
care transport team was not used. [24] In any population of patients with a high risk for
cardiopulmonary deterioration, consideration must be given to balancing the potential benefit
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of using a critical care transport team and the risk of holding the patient in the emergency
department for a longer time period until the specialty team is available.
For the above reasons, patients who present with symptomatic myocarditis are best trans‐
ported to a tertiary care center with a critical care transport team. These patients are at high
risk for deteriorating during transport, and often require urgent interventions upon arrival at
the receiving hospital. Helicopter transport may be faster than ground transport, although this
is not always true in urban environments or if the involved facilities do not have an on-site
helipad. [28] Helicopter transport guidelines have identified pediatric patients with sympto‐
matic myocarditis as appropriate candidates for helicopter transport. [29] While an efficient
mode of transport, medical helicopters have maximum distance limitations. There are also
strict weather and altitude limitations to helicopter transport, which may affect ground and
fixed wing transport to a lesser degree. A patient requiring frequent assessment or interven‐
tions may be challenging to care for in a helicopter due to noise, lack of space making access
to the patient challenging and turbulence in flight. Additionally in a helicopter, and certainly
in a fixed wing vehicle, it may be more difficult to divert to a different receiving facility should
the patient become acutely unstable for transport. There is no evidence looking at pediatric
myocarditis and ideal modes of transport. Data from adult patients shows that there are
conflicting reports about the efficacy of different modes of transport, specifically helicopter
versus ground transport. In 2012 a retrospective cohort study showed that among patients
with major trauma admitted to level I or level II trauma centers, transport by helicopter
compared with ground services was associated with improved survival to hospital discharge.
[30] While there are earlier studies in agreement with these findings, other studies in the adult
population have failed to show a benefit of helicopter transport. [31]- [34]
In summary, choosing a team and mode of transport for a patient is complex. There are many
factors influencing decision-making surrounding patient transport. The medical team should
consider the patient’s anticipated medical needs and the risks of destabilization during
transport, the urgency of the treatments needed at the receiving facility, transport logistics
such as altitude, weather and distance, and the team availability and experience. [35]
4.3. Treatment
There are currently no specific therapies for acute fulminant myocarditis. The mainstay of
therapy is supportive care to maintain cardiac output including mechanical ventilation,
inotropic support and, if tolerated, afterload reduction and diuresis. For transport purposes
intubation, ventilation and inotropic support play a larger role than other support strategies.
In adult populations there have historically been more options for ventricular assist devices.
However, pediatric assist devices have been successfully developed. In a recent study of the
Excor Pediatric ventricular assist device (Berlin Heart), Fraser et al demonstrated that survival
rates for patients awaiting heart transplant were significantly higher with the ventricular assist
device than with ECMO. [36] This data is not specific for myocarditis, but is promising that
assist devices can be effectively used in the pediatric population. Currently, the majority of
patients with refractory cardiogenic shock and/or severe respiratory failure will likely require
ECMO for ongoing support.
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4.3.1. Intubation and sedation
In patients with evidence of pulmonary edema the risk of worsening hypoxemia and potential
for respiratory acidosis is concerning, as neither would be well tolerated from a cardiac
standpoint. As respiratory demands increase to compensate for these issues, the oxygen
consumption of the respiratory muscles can increase up to eightfold. [37] Intubation and
mechanical ventilation will reduce respiratory muscle oxygen consumption, and thus overall
myocardial oxygen demand. [37] The risks of the induction for intubation should be carefully
weighed against these benefits, but declining status may force a clinician to proceed with
endotracheal intubation prior to transport.
In general, positive pressure ventilation reduces left ventricular wall tension and left ventric‐
ular afterload, and therefore may improve cardiac output by this mechanism. However, other
cardiopulmonary interactions associated with intubation and positive pressure ventilation
may precipitate low cardiac output or cardiac arrest in a patient with biventricular failure.
Those potentially harmful interactions include cessation of right sided venous return during
the transition from spontaneous breathing to positive pressure ventilation, and systemic
vasodilation and negative inotropy induced by medication used for induction of anesthesia.
If possible, it is important to ensure that the patient is euvolemic prior to induction to preserve
right ventricular preload upon initiation of positive pressure ventilation. It is also advisable
to have an inotropic agent either initiated or prepared to infuse to support biventricular
function. [38]The choice of specific induction agents is less important than recognizing that
patients in failure will likely have limited contractile reserve, will be relatively preload
dependent and will not respond well to rapid changes in afterload. [39] The choice of the
appropriate medication for induction of anesthesia for intubation is important. Any agent may
precipitate vasodilation and cardiac depression. Etomidate is well-known for a low rate of
adverse hemodynamic effects, and the direct sympathomimetic effects of ketamine may be
particularly beneficial in shock states. [40] Carefully titrated low-dose fentanyl may also
provide appropriate levels of sedation and analgesia with a more favorable cardiac profile.
Midazolam, propofol, and barbiturates are all likely to trigger hypotension at induction doses
and should therefore be avoided. Atropine premedication may be considered in pediatric
patients with bradycardia, though many patients with myocarditis are tachycardic on
presentation. [38]
The adverse hemodynamic effects of positive pressure ventilation on right sided venous return
may be ameliorated by using a strategy to minimize mean airway pressure, thus reducing
intrathoracic pressure. This includes avoiding lung hyperinflation, minimizing peak inspira‐
tory pressures, the use of short inspiratory times and adequate expiratory times and conser‐
vative use of positive end-expiratory pressure (PEEP). While PEEP may be helpful in managing
pulmonary edema and hypoxemia, it should be used with caution as it may lead to decreased
right ventricular preload and increased right ventricular afterload.
4.3.2. Rate control
Both tachycardia and bradycardia can pose risks to a pediatric patient in acute heart failure.
Arrhythmias must be quickly recognized and treated. Transcutaneous pacing has been
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recognized as an easy, safe, and effective temporary measure of rate control but may require
sedation and likely requires analgesia in the pediatric patient. [41]- [44] As mentioned,
administering sedation in a pediatric patient with myocarditis and cardiovascular compromise
could lead to further hemodynamic instability. Initiation of catecholamines such as dopamine
may provide benefit in patients with complete heart block by increasing the ventricular escape
rate to improve systemic perfusion in transport and should be considered before initiation of
transcutaneous pacing in hemodynamically stable patients. However, when using such agents
care should be taken not to acutely increase left ventricular afterload.
4.3.3. Afterload reduction
Management of heart failure should be employed if the patient can tolerate diuresis and
afterload reduction, but is probably not advisable in the acute setting. Ideally this management
would include diuretics to lower filling pressures and angiotensin-converting enzyme (ACE)
inhibitors to reduce systemic vascular resistance and left ventricular afterload. Beta-blockade
may be used as well, however the only randomized controlled trial of beta-blockade for
treatment of pediatric heart failure failed to demonstrate a benefit. [45] Furthermore using a
beta-blocker in the acute setting may complicate resuscitation efforts should a patient have
critically compromised output or lose circulation altogether. In patients with significant
dysfunction and diminished cardiac output systemic inodilators such as milrinone, are often
useful if tolerated. Due to the risk of systemic hypotension and some risk of worsening
myocardial dysfunction these interventions are best started in a tertiary care setting, not during
transport.
4.3.4. Levosimendan
Levosimendan is a positive ionotrope and functions by binding to cardiac troponin C to
increase calcium sensitivity of myocytes. It also has vasodilatory effects in arterial, venous and
coronary vasculature, which leads to afterload reduction and better matching of myocardial
oxygen demand. [46]- [49] Therefore despite improving ventricular function, levosimendan
does not significantly increase myocardial oxygen demand. Levosimendan is currently not
FDA approved, so there is no collective experience with it the US centers. There are case reports
of levosimendan being used successfully in both adult and pediatric myocarditis. [50]- [52]
However, there are no larger, prospective studies to provide adequate evidence for routine
use at this point. It remains unclear what potential benefit this drug would have in critical care
transport.
4.3.5. IVIG
The benefit of immune modulation remains controversial, and is not usually an adjunct to
consider during acute transport management. Intravenous immunoglobulins (IVIG) are the
most commonly used immune modulator in myocarditis. Drucker et al. showed a statistically
significant improvement in survival in pediatric patients treated with IVIG. [53] However
McNamara conducted a randomized control trial in adults and failed to show any difference
in survival among those treated with IVIG. [54] The data on the use of immunosuppressive
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agents such as prednisone, azathioprine and cyclosporine is not yet convincing. When the
existing data was examined in a meta-analysis, Hia et al were not able to find statistical
significance for improved outcomes. [55] That said, many centers currently use IVIG in the
treatment of myocarditis and in certain cases immunosuppressive therapy may improve
outcomes. [9], [56]
4.3.6. Mechanical support
In severe cases of cardiogenic shock patients may require rescue with veno-arterial (VA)
ECMO or ventricular assist devices (VADs). Veno-venous (VV) ECMO is typically reserved
for patients with predominant pulmonary failure. Whether requiring ECMO or VAD support,
patients are best cared for in tertiary care centers with established ECMO programs.
VA-ECMO should be considered in patients with myocarditis only once routine supportive
therapies have failed. [57], [58] While potentially life-sustaining in these cases, ECMO is not
without risk. There is significant chance for hemorrhage, infectious complications and vascular
injury during cannulation. There is also a risk of cerebral and coronary hypoxia and stroke.
Less common, but potentially life-threatening are thrombotic events. Another complicating
issue, which may ultimately compromise ventricular recovery, is left atrial hypertension
secondary to poor ventricular function and decreased ejection while on ECMO. Left atrial
hypertension can result in increased left ventricular end-diastolic pressure, subendocardial
ischemia and pulmonary edema. There is no consensus on indications or technique for left
atrial decompression, but it has been shown to relieve pulmonary edema and improve
hemodynamics in one study. [59]
In experienced centers, ECMO is often successfully employed as a short-term rescue therapy
for refractory cardiopulmonary failure. Though there is extensive experience with pediatric
ECMO, in addition to potential complications there are also other significant limitations: need
for sedation, lack of mobility, and relatively short lifespan of the circuit. In cases where failure
is more chronic, or transplant is needed, a VAD may be a more appropriate intervention. VADs
are available as right (RVAD), left (LVAD) and bi-ventricular (BiVAD) devices. They have been
used for ventricular recovery, destination devices and as bridges to heart transplant. A recent
prospective, single-group pediatric trial showed that survival rates to transplant were
significantly higher with the ventricular assist device than with ECMO. [36] Complications of
assist devices are significant and similar to ECMO, including bleeding, stroke, infection and
thrombotic events.
4.3.7. Special consideration: ECMO on transport
Pediatric ECMO is offered in many centers worldwide [60], and increasingly ECMO centers
are  confronted with  the  request  to  transport  a  patient  on  ECMO.  A few centers  in  the
United States and in Europe reported these transports in the literature. [61]- [67] One group
reported the successful transport of  68 children on ECMO, traveling a distance between
eight and 7500 miles. Overall ECMO survival was comparable with in-house survival on
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ECMO  at  the  same  institution.  More  importantly,  no  deaths  occurred  during  ECMO
transport. [66]
Bringing an ECMO team to a referring facility to place an unstable patient on extracorporeal
support and then transport the patient back to a tertiary care center on ECMO has been
suggested and, in a few cases, successfully completed. The logistics of providing such a service
are very complicated. Based on military data, Coppola and colleagues reported that the ECMO
transport team consists of 10-15 staff members, including a mission commander, a pediatric
intensivist, a pediatric cardiologist, a pediatric surgeon, two to three ECMO specialists, nurses
and respiratory therapists [66]. A civilian team reported using a team consisting of two nurses,
two ECLS specialists, an attending physician, and a resident. [67] ECMO transports to date
have been completed in ground, fixed-wing, and rotor-wing vehicles. The complexity of
ECMO transport warrants careful discussion about feasibility and resource utilization, but
may be successfully accomplished. That said, early referral to an ECMO center while the
patient may be safely transported without ECMO is the preferred option.
5. Conclusions
Myocarditis presents with a broad range of relatively non-specific symptoms and for that
reason is difficult to diagnose, but must remain on the list of differential diagnoses for any
child presenting with acute heart failure or other signs of cardiac deterioration. Acute fulmi‐
nant myocarditis is life-threatening and requires careful, proactive management. When
treating the pediatric patient with acute fulminant myocarditis clinicians should consider the
benefits of intubation, inotropic infusions, and transcutaneous pacing as temporizing meas‐
ures especially during the transport phase, recognizing that any of those interventions can lead
to further deterioration of the patient if not performed with great caution. Prompt and safe
transport to a pediatric tertiary care center should be ensured. The option of early management
with ECMO or other assist devices seems beneficial and should be considered when making
triage decisions.
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